'Pharma bro' Martin Shkreli released from prison early to halfway house

NEW YORK, NY - AUGUST 4: (L to R) Lead defense attorney Benjamin Brafman walks with former pharmaceutical executive Martin Shkreli at the U.S. District Court for the Eastern District of New York, August 4, 2017 in New York City. (Photo by Drew Angere

Notorious "pharma bro" Martin Shkreli was released from federal prison into a halfway house on Wednesday, the Bureau of Prisons confirmed to Fox News Digital.

Shkreli was sentenced to seven years in federal prison on fraud charges in 2017, and his release date was originally scheduled for September 2022. Shkreli was being held at the FCI Allenwood facility in Pennsylvania. A spokesperson for the facility confirmed Shkreli's transfer on Wednesday.

"We can confirm Martin Shkreli transferred on May 18, 2022, from the Federal Correctional Institution (FCI) Allenwood Low to community confinement overseen by the Bureau of Prisons' (BOP) New York Residential Reentry Management (RRM) Office," the official stated in an email.

RELATED: Exclusive: Pharmaceutical exec. Martin Shkreli speaks out


NEW YORK, NY - AUGUST 4: Former pharmaceutical executive Martin Shkreli points as he exits the courthouse in New York City. (Photo by Drew Angerer/Getty Images)

Shkreli posted a photo of himself apparently free Wednesday morning, with the caption "Getting out of real prison is easier than getting out of Twitter prison."

Shkreli remains banned from Twitter.


Shkreli, a former pharmaceutical CEO, became notorious after hiking the price of a live-saving AIDS drug by more than 4000% overnight in 2015.

RELATED: 'Pharma Bro' company reaches $40M settlement in price-gouging case

He was ultimately convicted of defrauding investors by lying about the performance of two hedge funds he ran, as well as by hiding his ownership of some stock in Retrophin, a pharmaceutical company.

He was ordered to pay out more than $65 million in the case, in addition to his incarceration.

LINK: Get updates and more on this story at foxbusiness.com.